Previous 10 | Next 10 |
2023-10-03 07:23:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are a major topic this morning as we check out the biggest ones worth watching on Tuesday! Moving stocks this morning are share delistings, Q3 earnings estimates and...
2023-08-31 17:13:00 ET More on Neximmune Neximmune GAAP EPS of -$0.29 NexImmune stock surges ~55% on preclinical data linked to T cell response NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers NexImmune promotes insi...
Company retains core capabilities to continue to advance its nanoparticle injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseases GAITHERSBURG, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel app...
2023-08-11 16:12:17 ET More on Neximmune NexImmune stock surges ~55% on preclinical data linked to T cell response NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers NexImmune promotes insider Mathias Oelke to chief scientific...
NEXI-001 data presented at ASCO 2023 demonstrates proof-of-concept in patients with relapsed AML after allogeneic hematopoietic cell transplantation (HCT) and refractory to additional chemotherapy or salvage treatments; one patient continues to show no evidence of disease at nine months P...
- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001 is well tolerated with a favorable safety profile, including no grade > 3 treatment related events as of May 2023 - Robust immune response with...
AIM nanoparticle approach can identify select EBV-specific T cell defects in patients with multiple sclerosis and may enable killing of EBV+ cells believed to be a contributing factor in this disease Data suggests a potential therapeutic role for AIM multi-antigen-specific products in mul...
2023-05-16 03:56:53 ET Neximmune press release ( NASDAQ: NEXI ): Q1 GAAP EPS of -$0.37. Cash and cash equivalents for the Company as of March 31, 2023 were $22.3 million compared to $34.6 million at December 31, 2022. Based upon current operating plans, NexIm...
Company has initiated pre-IND discussions with the FDA for its first AIM INJ indication NEXI-001 Phase I data to be presented at ASCO 2023 in June GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel appro...
GAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, to...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...